# 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

> **NCT05543317** · NA · COMPLETED · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 27 (actual)

## Conditions studied

- Tumor, Solid
- Positron-Emission Tomography

## Interventions

- **DIAGNOSTIC_TEST:** 18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT

## Key facts

- **NCT ID:** NCT05543317
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543317, "68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05543317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*